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Abstract 
Pulmonary arterial hypertension is an infre-
quent but nevertheless serious life-threaten-
ing severe complication of HIV infection. It can
be treated with bosentan and oral anticoagu-
lants.  Bosentan  could  induce  the  aceno-
coumarol metabolism and it increases the INR
values.  Until  now,  no  study  of  interaction
between bosentan and oral anticoagulants in
HIV  patients  has  reported.  So  we  present  a
case of this interaction between these drugs
and we reviewed MEDLINE to identify all the
papers published so far. In our case, several
weeks  after  increasing  dose  of  bosentan
acenocoumarol  dose  had  to  be  progressively
increased  to  70  mg/week  (+33%)  without
obtaining  an  adequate  INR  level  (2.0-3.0).
Forty-nine days later, we achieved a therapeu-
tic INR with 90 mg/week of warfarin. The use
of bosentan and oral anticoagulants together
in these patients require a closer monitoring
during first weeks of treatment, after increas-
ing the bosentan dose and even during longer
periods of time.
Introduction
Pulmonary  arterial  hypertension  (PAH)  is
an  infrequent  but  nevertheless  serious  life-
threatening severe complication of HIV infec-
tion. It is associated with an increase of pul-
monary vascular resistance, pulmonary artery
pressure, right-ventricular failure and death.
Bosentan, a dual endothelin-1 receptor antag-
onist, is indicated in the treatment of PAH. It
also  improves  exercise  capacity,  New  York
Heart  Association  (NYHA)  functional  class,
quality  of  life  as  well  as  cardiopulmonary
hemodynamics, cardiac geometry, and cardiac
function in these patients. The combination of
bosentan with antiretroviral therapy appears
to be safe and to have no adverse impact on the
control  of  HIV  infection.1 However,  PAH
patients  present  a  high  risk  of  developing
thromboembolism and thrombosis. Oral anti-
coagulants have been shown to improve sur-
vival  in  patients  with  pulmonary  hyperten-
sion.2 Nowadays, HIV patients have a greater
life expectancy compared to a few years ago.
They can be treated with many drugs hepati-
cally metabolized. Bosentan could induce both
cytochrome  P450  (CYP)  3A4  and  CYP2C9
enzymes,  which  are  also  involved  in  aceno-
coumarol metabolism, and it is eliminated by
biliary excretion.1 An alteration in the antico-
agulant  effect  might  increase  the  risk  of
haematological  disturbances.  Until  now,  the
clinical data regarding the interaction between
bosentan or ritonavir with oral anticoagulants
(either warfarin or acenocoumarol) are limit-
ed.1,3-5 No study of interaction between bosen-
tan and acenocoumarol has reported so far. So,
we  present  a  case  of  interaction  between
bosentan  and  oral  anticoagulants  in  an  HIV
patient and we made a systematic review in
MEDLINE  to  identify  published  papers  in
English  to  identify  cases  of  interaction
between bosentan and oral anticoagulants in
HIV patients. The keywords used in the search
were acenocoumarol, warfarin, bosentan, drug
interactions, protease inhibitors, International
Normalized  Ratio  and  pulmonary  arterial
hypertension. Initially, we analyzed all cases
found.  The  search  covered  the  period  from
1966 to 2011, the last search made was on 29
Jul 2011. The cases selected were those where
there was interaction between the three drugs:
bosentan,  oral  anticoagulants  and  protease
inhibitors.
Case Report
In  August  2009,  a  48-year-old  Caucasian
male was diagnosed with PAH, associated with
HIV  infection.  He  also  had  a  double  aortic
lesion with dilatation of the right cavities and
he was being treated with acenocoumarol. The
patient was an ex-smoker, ex-parenteral drug
addict and had previously been diagnosed with
chronic  but  stable  hepatitis  C  (Child-Pugh
Class A). On 24th October 2009, he came to our
Haematology Department for anticoagulation
control. Over the previous year, his medication
regimen had included lopinavir 200 mg/riton-
avir 50 mg 2 capsules twice daily and emtric-
itabine  200  mg/tenofovir  300  mg  once  daily.
Over the previous month, he had taken aceno-
coumarol 56 mg/week (achieving an INR val-
ues in the therapeutic range, 2.0-3.0). In the
last week of September, he began treatment
with bosentan 62.5 mg twice daily. One month
later, the bosentan dose was increased from
62.5 mg to 125 mg and two weeks after that, he
presented  an  international  normalized  ratio
(INR) of less than 2. The acenocoumarol dose
was progressively increased up to 56 mg/week
to obtain an adequate INR level. In the last
week of March 2010, the patient again present-
ed with an INR of less than 2 (bosentan 125mg
twice daily initiated on 8th March 2010). The
acenocoumarol dose was raised to 70 mg/week
(+33%) but failed to produce an adequate INR
level. On 21th April 2010, in an attempt to avoid
an interaction between bosentan and aceno-
coumarol, this was stopped. Then, warfarin 35
mg/week and bemiparin 7500 IU daily was ini-
tiated.  Forty-nine  days  later,  we  achieved  a
therapeutic INR with 90 mg/week (+157%) of
warfarin (Table 1). He denied using alcohol or
tobacco, having changed his dietary intake, or
either missing or taking extra doses of oral
anticoagulants.  Viral  load  remained  unde-
tectable (< 50 HIV RNA copies/mL) and lym-
phocytes  CD4  +  >300  cells/mm3 during  this
period. Dose of lopinavir /ritonavir remained
unchanged  during  bosentan  and  aceno-
coumarol  treatment.  After  three  months  of
treatment levels of INR remained between 2-3.
The Horn Drug Interaction Probability Scale
indicated  a  probable  interaction  between
bosentan, acenocoumarol and lopinavir/riton-
avir.6
Discussion
Bosentan could increase the metabolization
of both oral anticoagulants and develop a clin-
ically-relevant decrease of oral anticoagulant
concentrations. In our patient, it was neces-
sary  to  significantly  increase  the  dose  of
acenocoumarol and warfarin to try achieving a
therapeutic INR. Spangler and Saxena report-
ed that a patient treated with bosentan and
warfarin needed a warfarin dose increase of
43% (75 mg/wk) to maintain the therapeutic
INR.3 In addition, Murphey and Hood reported
a warfarin dose increase of 64% (45 mg/wk).4
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first 10 days of treatment with bosentan while
in our case it occurred on the 40th day and he
needed a higher dose (20-50%) of warfarin to
reach a therapeutic INR.2,3 In other reported
cases, after increasing the bosentan dose our
patient presented a delay in the response of
more than 1 month.3 In other case, Llibre et al.
reported a dramatic drop of INR after concomi-
tant  treatment  with  ritonavir  and  aceno-
coumarol.5 In our patient, this interaction was
not shown. After a month of treatment with
lopinavir/ritonavir  and  acenocoumarol,  our
patient presented a stable value of INR, viral
load and CD4 + lymphocytes. The INR values
only  dropped  drastically  after  receiving  two
months  treatment  of  bosentan  and  aceno-
coumarol. He required very high doses of war-
farin in order to achieve an INR within the
therapeutic range. The dosage of 90mg/week
could indicate a possible induction of warfarin
metabolism. Dingemanse and van Giersbergen
observed an increase in bosentan concentra-
tion up to 48-fold during the first 4 days of
coadministration  with  lopinavir/ritonavir.7 In
our case, lopinavir/ritonavir did not seem to
raise bosentan level. However, bosentan could
significantly  compromise  the  metabolism  of
both oral anticoagulants.8
Several  mechanisms  might  explain  this
interaction.  Firstly,  in  patients  with  mild
hepatic impairment (Child-Pugh class A), such
as the case in our patient, an increase of the
bosentan dose along with its active metabolite,
Ro 48-5033, has been reported.9 In addition,
Dingemanse  and  van  Giersbergen  reported
that the exposure to bosentan in patients with
PAH could present with low hepatic clearance.7
An increase in the bosentan dose could reduce
the bile salt export pump level by up to 78%,
increasing  its  half-life.10 In  our  patient,  the
delay in the onset of symptoms could be relat-
ed  to  a  reduction  in  the  hepatic  uptake  of
bosentan  and  a  reduction  of  the  induction
effect on CYP2C9. Secondly, bosentan might
induce CYP3A4 and CYP2C9 activity - aceno-
coumarol and warfarin mainly being metabo-
lized by CYP2C9. This might be related to an
increase in the elimination of the oral antico-
agulant and the dramatic drop in the INR val-
ues.  However,  it  did  not  seem  to  affect  the
effectiveness  of  lopinavir/ritonavir  and  dose
adjustment  of  this  might  not  be  required.1
Other factors, such as genetic polymorphism
in CYP2C9 (or in CYP2C29, a murine homo-
logue  of  human  CYP2C9),11 could  represent
another potential complicating factor in this
interaction  and  should  be  studied  in  these
patients. So, the genetic contribution to varia-
tion in dose requirements seems to be more
pronounced for warfarin than acenocoumarol.8
Patients treated with bosentan, oral antico-
agulants may need a significant increase in
the anticoagulant dose to achieve an INR in
the  therapeutic  range.  However,  randomised
controlled  trials  comparing  the  dosage  and
safety of bosentan and oral anticoagulants in
HIV patients are needed. Until then, the use of
bosentan  and  oral  anticoagulants  in  these
patients not only seems to require closer mon-
itoring  during  the  first  weeks  of  treatment
with bosentan, or after an increase in its dose,
but for even longer periods of time.
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Table 1. Anticoagulant history.
Date INR* Anticoagulant dose, mg/wk Notes
10/24/09 2.2 52.5 (AC) Bosentan dose ↑from 62.5-125mg°
11/10/09 1.5 52.5 AC dose ↑to 53.5 mg/wk
11/19/09 1.4 53.5 AC dose ￿↑to 56 mg/wk
11/26/09 1.8 56 -
12/04/09 2.8 56 -
2/15/10 2.6 56 -
3/23/10 1.6 56 Bosentan 125 mg BID initiated on
3/08/10; AC dose ↑to 63 mg/wk
4/14/10 1.7 63 AC dose ￿↑to 70 mg/wk
4/21/10 1.7 70 AC was stopped. Warfarin 35 mg/wk
and subcutaneous bemiparin 7500
IU/day was initiated
4/26/10 1.2 35 Warfarin dose ￿↑to 42.5 mg/wk
5/06/10 1.3 42.5 Warfarin dose ￿↑to 50 mg/wk
5/13/10 1.3 50 Warfarin dose ￿↑to 57.5 mg/wk.
5/20/10 1.4 57.5 Warfarin dose ￿↑to 62.5 mg/wk
5/27/10 1.4 62.5 Warfarin dose ￿↑to 70 mg/wk
6/03/10 1.5 70 Warfarin dose ￿↑to 90 mg/wk
6/09/10 3 90 Bemiparin was stopped
6/29 2.5 90 -
7/14 2 90 -
8/05/10 2.3 90 -
AC, acenocoumarol; BID, twice daily; *INR, International Normalized Ratio (therapeutic range, 2.0-3.0); °Bosentan initiated at 62.5 mg BID on
9/24/09.
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